Bristol-Myers Squibb posted third-quarter revenue of US$12.22 billion, exceeding consensus of about US$11.8 billion, driven by Opdivo sales of US$2.53 billion (+7 %) and Eliquis sales of US$3.75 billion (+25 %). The growth-portfolio (including these two) rose 18 % to US$6.9 billion, offsetting a 59 % decline in Revlimid to US$575 million. The company upgraded its full-year revenue guidance to a range of US$47.5 billion–US$48 billion (up from US$46.5 billion–US$47.5 billion). CEO Christopher Boerner emphasised acquisitions and earlier-stage pipeline investments as priorities.